Q1 Earnings Estimate for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX - Free Report) - Leerink Partnrs reduced their Q1 2025 EPS estimates for Quanterix in a research note issued on Monday, March 17th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.69) for the quarter, down from their prior estimate of ($0.58). The consensus estimate for Quanterix's current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix's Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Separately, Canaccord Genuity Group decreased their price target on Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th.

Quanterix Price Performance

Shares of NASDAQ:QTRX traded down $0.02 during trading on Thursday, hitting $7.22. The company had a trading volume of 705,141 shares, compared to its average volume of 507,104. The stock has a market cap of $279.96 million, a price-to-earnings ratio of -6.81 and a beta of 1.33. The company has a fifty day simple moving average of $8.18 and a two-hundred day simple moving average of $10.83. Quanterix has a one year low of $6.30 and a one year high of $24.05.

Remove Ads

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The business had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Ameriprise Financial Inc. raised its holdings in shares of Quanterix by 111.3% in the fourth quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company's stock worth $34,079,000 after buying an additional 1,688,680 shares during the period. Portolan Capital Management LLC increased its stake in Quanterix by 2.7% in the fourth quarter. Portolan Capital Management LLC now owns 2,587,824 shares of the company's stock worth $27,509,000 after purchasing an additional 67,138 shares during the period. Vanguard Group Inc. lifted its position in shares of Quanterix by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company's stock worth $23,569,000 after purchasing an additional 19,386 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Quanterix by 6.0% in the fourth quarter. Millennium Management LLC now owns 2,185,101 shares of the company's stock worth $23,228,000 after purchasing an additional 122,969 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new position in Quanterix in the 4th quarter worth about $11,290,000. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.